glp-1 aspiration receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have become incredibly common in diabetes and weight-management care, and they're now showing up more and more in the perioperative setting. These How should we approach patients
Description
Patients achieved substantial weight loss during the initial GLP-1 RA phase (~1822% at 12 months), which was subsequently maintained after its discontinuation, with total weight reduction reaching 25.5% (95% CI 23.127.9%) at 593 days, with most patients on metformin
FDA listed warning letters issued to internet retailers/providers of various compounded drug under the term Telehealth on its webpage: Compounding: Inspections, Recalls, and other Actions
Even at lower doses, GLP-1 receptor agonists may provide powerful health benefits
Innovative Dual-Action Mechanism Tirzepatides unique combination of GLP-1 and GIP receptor agonism targets appetite regulation and glucose control more comprehensively
Bariatric Fusion GLP-ONE + Receptor Activator features two clinically validated botanical ingredients: hops extract (20% xanthohumulone) and copaiba extract (10% beta-caryophyllene)
